EUVIMEDEUVIMED entdecken
Crossref

A metabolic dependency of EBV can be targeted to hinder B cell transformation

Bojana Müller-Durovic iD, Jessica Jäger iD, Christine Engelmann, Patrick Schuhmachers iD, Sabine Altermatt, Yannick Schlup, Urs Duthaler iD, Celia Makowiec iD, Gunhild Unterstab iD, Sarah Roffeis iD, Erta Xhafa iD, Nadine Assmann iD und 22 weitere

Science · 05.07.2024 · 385 (6704)

DOI: 10.1126/science.adk4898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 05.07.2024. Verfasst von Bojana Müller-Durovic und 33 weiteren Autor:innen. Beteiligte Einrichtung: Immunobiology Laboratory, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Adenosine Triphosphate, B-Lymphocytes, Cell Transformation, Viral, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

After infection of B cells, Epstein-Barr virus (EBV) engages host pathways that mediate cell proliferation and transformation, contributing to the propensity of the virus to drive immune dysregulation and lymphomagenesis. We found that the EBV protein EBNA2 initiates nicotinamide adenine dinucleotide (NAD) de novo biosynthesis by driving expression of the metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) in infected B cells. Virus-enforced NAD production sustained mitochondrial complex I activity, to match adenosine triphosphate (ATP) production with bioenergetic requirements of proliferation and transformation. In transplant patients, IDO1 expression in EBV-infected B cells, and a serum signature of increased IDO1 activity, preceded development of lymphoma. In humanized mice infected with EBV, IDO1 inhibition reduced both viremia and lymphomagenesis. Virus-orchestrated NAD biosynthesis is therefore a druggable metabolic vulnerability of EBV-driven B cell transformation, opening therapeutic possibilities for EBV-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine TriphosphateB-LymphocytesCell Transformation, ViralEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanIndoleamine-Pyrrole 2,3,-DioxygenaseNADAnimalsHumansMiceCell ProliferationElectron Transport Complex ILymphomaViral ProteinsViremia

Substanzen

Adenosine TriphosphateEBNA-2 protein, Human herpesvirus 4Electron Transport Complex IEpstein-Barr Virus Nuclear AntigensIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseNADViral Proteins

Autor:innen und Institutionen

  • Immunobiology Laboratory, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
  • Clinical Pharmacology Laboratory, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
  • Axolabs GmbH, Kulmbach, Germany.
  • Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK.
  • Bioinformatics Facility, Department of Biomedicine, University Basel and University Hospital of Basel, Basel, Switzerland.

ORCID-Profile: Bojana Müller-Durovic, Jessica Jäger, Patrick Schuhmachers, Urs Duthaler, Celia Makowiec, Gunhild Unterstab, Sarah Roffeis, Erta Xhafa, Nadine Assmann, Fredrik Trulsson, Rebekah Steiner, Joy Edwards-Hicks, Leyla Develioglu, Robert Ivanek, Tarik Azzi, Philippe Dehio, Christoph Berger, Dmitry Kuzmin, Sophie Saboz, Josef Mautner, Marco Geigges, Darya Palianina, Nina Khanna, Stefan Dirnhofer, Christian Münz, Glenn R Bantug, Christoph Hess

Zitieren

APA

Müller-Durovic, B., Jäger, J., Engelmann, C., Schuhmachers, P., Altermatt, S., Schlup, Y., Duthaler, U., Makowiec, C., Unterstab, G., Roffeis, S., Xhafa, E., Assmann, N., Trulsson, F., Steiner, R., Edwards-Hicks, J., West, J., Turner, L., Develioglu, L., Ivanek, R., …, & Hess, C. (2024). A metabolic dependency of EBV can be targeted to hinder B cell transformation. Science, 385(6704). https://doi.org/10.1126/science.adk4898

Vancouver

Müller-Durovic B, Jäger J, Engelmann C, Schuhmachers P, Altermatt S, Schlup Y, et al. A metabolic dependency of EBV can be targeted to hinder B cell transformation. Science. 2024;385(6704). doi:10.1126/science.adk4898

BibTeX
@article{MllerDurovic2024,
  author = {Müller-Durovic, Bojana and Jäger, Jessica and Engelmann, Christine and Schuhmachers, Patrick and Altermatt, Sabine and Schlup, Yannick and Duthaler, Urs and Makowiec, Celia and Unterstab, Gunhild and Roffeis, Sarah and Xhafa, Erta and Assmann, Nadine and Trulsson, Fredrik and Steiner, Rebekah and Edwards-Hicks, Joy and West, James and Turner, Lorinda and Develioglu, Leyla and Ivanek, Robert and Azzi, Tarik and Dehio, Philippe and Berger, Christoph and Swiss Transplant Cohort Study, Swiss Transplant Cohort Study and Kuzmin, Dmitry and Saboz, Sophie and Mautner, Josef and Löliger, Jordan and Geigges, Marco and Palianina, Darya and Khanna, Nina and Dirnhofer, Stefan and Münz, Christian and Bantug, Glenn R and Hess, Christoph},
  title = {A metabolic dependency of EBV can be targeted to hinder B cell transformation},
  journal = {Science},
  year = {2024},
  volume = {385},
  number = {6704},
  doi = {10.1126/science.adk4898}
}
Kostenlos starten →